[Progress in research of prophylactic therapy in contacts of rifampicin-resistant tuberculosis patients].
Zhonghua Liu Xing Bing Xue Za Zhi
; 44(3): 470-476, 2023 Mar 10.
Article
en Zh
| MEDLINE
| ID: mdl-36942344
ABSTRACT
Tuberculosis (TB) prophylactic therapy for latent infection, which can reduce the risk for the development of active TB, is an important measure in TB control. China recommends prophylactic therapy for latent tuberculosis infection (LTBI) in some key populations to reduce the risk for TB. Contacts of patients with multi-drug and rifampicin-resistant TB (MDR/RR-TB) are at high risk for the infection with drug-resistant pathogen, however, no unified prophylactic therapy regimen has been recommended for LTBI due to exposure to MDR/RR-TB patients. This paper summarizes the current MDR/RR-TB prophylactic therapy regimen and its protection effect based on the results of the retrieval of literature, guidelines, expert consensus and technical specifications to provide reference for the prevention and control of LTBI.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Tuberculosis
/
Tuberculosis Resistente a Múltiples Medicamentos
/
Tuberculosis Latente
Tipo de estudio:
Guideline
Límite:
Humans
País/Región como asunto:
Asia
Idioma:
Zh
Revista:
Zhonghua Liu Xing Bing Xue Za Zhi
Año:
2023
Tipo del documento:
Article
País de afiliación:
China